ICYMI: Lilly's new drug combo beats Ozempic's rival — by a wide margin #WeightLoss #ObesityTreatment
New phase 2b trial of aleniglipron, an oral GLP-1 receptor agonist for weight management, published in Nature Medicine. Oral formulations could overcome injecti… #Aleniglipron #Clinicaltrial #GLP1agonist #NatureMedicine #Obesitytreatment #Aleniglipron #Clinicaltrial #GLP1agonist #NatureMedicine…
